The passage states:
- Colfax Beta-80 is a rare genetic defect primarily found in people of Scandinavian descent.
- Over 97% of carriers are from Denmark, Norway, or Sweden.
- Carriers are at a substantially higher risk for Lupus and related autoimmune diseases.
Let’s evaluate the options:
(A) People from Denmark are at a higher risk for Lupus than people of other, non-Scandinavian countries.
- This is plausible because the defect is primarily found in Scandinavians, and carriers are at higher risk for Lupus. However, the passage does not explicitly compare risk levels between Scandinavians and non-Scandinavians.
(B) Genetic engineering that eradicated this genetic defect would constitute a de facto cure for Lupus.
- This cannot be inferred. The passage does not suggest that Colfax Beta-80 is the sole cause of Lupus, so eliminating it would not necessarily cure Lupus.
(C) Finding a cure for Lupus would eliminate most of the health threats associated with the Colfax Beta-80 defect.
- This cannot be inferred. The passage does not state that Lupus is the only health threat associated with the defect.
(D) A person not of Scandinavian descent born with the Colfax Beta-80 defect is more likely to contract Lupus than is a Scandinavian who is born without this defect.
- This can be inferred. The passage states that carriers of the defect are at a substantially higher risk for Lupus, regardless of their descent.
(E) The majority of people who contract Lupus are either Scandinavian or of Scandinavian descent.
- This cannot be inferred. The passage does not provide data on the overall prevalence of Lupus or its distribution among populations.
The most reasonable inference is (D).
Answer: (D)